"Unsere Praxis besteht seit 1997 und ist seitdem etablierte Behandlungsstätte für onkologische und hämatologische Erkrankungen. Seit April 2009 arbeiten wir in modernen Praxisräumen im Medicinum. Wir arbeiten nach der Qualitätsmanagement-Richtlinie des Gemeinsamen Bundesausschusses. Zur kontinuierlichen Verbesserung unsere Arbeit nutzen wir das von der Kassenärztlichen Bundesvereinigung speziell für die Anforderungen in der ambulanten Patientenversorgung entwickelte Qualitätsmanagementverfahren QEP (Qualität und Entwicklung in Praxen). Die umfassende Betreuung unserer Patienten ist für uns Verpflichtung zu einer fachübergreifenden kollegialen Zusammenarbeit mit allen beteiligten Ärzten der Kliniken und Praxen."

During the past decade, Onkologische Schwerpunktpraxis conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Onkologische Schwerpunktpraxis" #1 sponsor was "German High-Grade Non-Hodgkin's Lymphoma Study Group" with 3 trials, followed by "AIO-Studien-gGmbH" with 1 trials sponsored, "Cytavis Biopharma GmbH" with 1 trials sponsored, "German CLL Study Group" with 1 trials sponsored and "Onco Medical Consult GmbH" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Onkologische Schwerpunktpraxis" #1 collaborator was "Charite University, Berlin, Germany" with 1 trials as a collaborator, "ClinAssess GmbH" with 1 trials as a collaborator, "Medical University Innsbruck" with 1 trials as a collaborator and "Roche Pharma AG" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Onkologische Schwerpunktpraxis" are "Lymphoma" (3 trials), "Advanced (Locally Advanced and Inoperable or Metastatic), PD-L1 IC-positive TNBC" (1 trials), "Chronic Lymphocytic Leukemia" (1 trials), "Colorectal Neoplasms" (1 trials) and "Extensive-stage Small Cell Lung Cancer" (1 trials). Many other conditions were trialed in "Onkologische Schwerpunktpraxis" in a lesser frequency.

Most popular intervention types in "Onkologische Schwerpunktpraxis" are "Drug" (8 trials), "Biological" (3 trials), "Radiation" (3 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "cyclophosphamide" (3 trials), "doxorubicin hydrochloride" (3 trials), "prednisone" (3 trials), "radiation therapy" (3 trials) and "vincristine sulfate" (3 trials). Other intervention names were less common.

The vast majority of trials in "Onkologische Schwerpunktpraxis" are 10 trials for "All" genders.

Currently, there are NaN active trials in "Onkologische Schwerpunktpraxis". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Onkologische Schwerpunktpraxis, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Onkologische Schwerpunktpraxis, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 5 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".